India  

Gilead's remdesivir gets conditional EU clearance

Video Credit: Reuters Studio - Duration: 00:59s - Published
Gilead's remdesivir gets conditional EU clearance

Gilead's remdesivir gets conditional EU clearance

The European Commission said Friday it had given conditional approval for the use of antiviral drug remdesivir in severe COVID-19 patients.

As Fred Katayama reports, that makes it the region's first authorized therapy to treat the virus.

0
shares
ShareTweetSavePostSend
 

💡 newsR Knowledge: Other News Mentions

European Commission European Commission Executive branch of the European Union

EU insists European companies could replace Huawei in 5G network [Video]

EU insists European companies could replace Huawei in 5G network

Nokia and Ericsson can replace Huawei if the Chinese tech giant were to be sidelined for security reasons, the European Commission said on Friday.View on euronews

Credit: euronews (in English)    Duration: 01:25Published
Full steam ahead: hydrogen train boosted by EU climate goals [Video]

Full steam ahead: hydrogen train boosted by EU climate goals

As the European Commission pushes for cleaner fuels to fight global warming, hydrogen could mean the end of the line for diesel-powered locomotives.View on euronews

Credit: euronews (in English)    Duration: 01:49Published
'Impasse' EU talks extended to Sunday [Video]

'Impasse' EU talks extended to Sunday

European Union leaders ended a second day of negotiations late on Saturday without a concrete plan to pump hundreds of billions of euros into their economies ravaged by coronavirus and would resume on Sunday. Conway G. Gittens has the details.

Credit: Reuters - Politics    Duration: 01:10Published
Coronavirus: no ''mini-Schengens", warns EU Commission VP [Video]

Coronavirus: no ''mini-Schengens", warns EU Commission VP

European Commission Vice President Margaritis Schinas talks to the Global Conversation about the future of Europe's border-free travel Schengen zone and what European solidarity should look like once Europe comes out of the coronavirus crisis.View on euronews

Credit: euronews (in English)    Duration: 08:13Published
EU plans tax overhaul to shore up post-lockdown economy [Video]

EU plans tax overhaul to shore up post-lockdown economy

It came as Brussels suffered a setback when a court rejected a European Commission demand that Apple should pay €13 billion in Irish back taxes.View on euronews

Credit: euronews (in English)    Duration: 01:53Published

Gilead Sciences American pharmaceutical company

Drugmaker Says Remdesivir Can Lower COVID-19 Death Risk By 62% [Video]

Drugmaker Says Remdesivir Can Lower COVID-19 Death Risk By 62%

The antiviral drug Remdesivir has proven to be effective in the treatment of COVID-19. According to UPI, the drug can lower the risk of death in COVID-19 patients by 62%. U.S. drugmaker Gilead Sciences reported the new data on Friday. Gilead said the results came from a comparative analysis among 312 patients in its Phase 3 clinical trial. There have been over 3.4 million confirmed cases of coronavirus in the U.S., with a death toll of 138,247 people.

Credit: Wochit News    Duration: 00:32Published
Gilead sparks Wall Street rally [Video]

Gilead sparks Wall Street rally

U.S. stocks rose Friday as a positive analysis on Gilead Sciences Inc's antiviral drug to treat COVID-19 helped to soothe investor worries over a record rise in coronavirus cases in the United States. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:20Published
Gilead says remdesivir cuts death risk [Video]

Gilead says remdesivir cuts death risk

Gilead Sciences said Friday additional data from a late-stage study showed its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill COVID-19 patients. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:04Published
Gilead to Charge $3,120 Per Patient for Typical Covid-19 Treatment [Video]

Gilead to Charge $3,120 Per Patient for Typical Covid-19 Treatment

Gilead is the pharmaceutical company behind a drug that’s been approved for COVID emergencies. The FDA officially announced the medicine could be used in treating COVID-19 patients. Gilead has now announced the drug will cost $3,120 per typical treatment course for insured individuals. Research has indicated the drug could cut the recovery time for hospitalized COVID-19 patients. It could shorten satsy by several days, reports Gizmodo.

Credit: Wochit News    Duration: 00:35Published

European Union European Union Economic and political union of European states

Sunak on Brexit talks: ‘There remain gaps’ on big issues [Video]

Sunak on Brexit talks: ‘There remain gaps’ on big issues

Chancellor Rishi Sunak says the government is making “good progress” on Brexit deal negotiations with the European Union ahead of the December 31st deadline but adds that “there remain gaps on a couple of big issues”. Report by Jonesia. Like us on Facebook at http://www.facebook.com/itn and follow us on Twitter at http://twitter.com/itn

Credit: ODN    Duration: 00:58Published
Brexit briefing: 141 days until the end of the transition period [Video]

Brexit briefing: 141 days until the end of the transition period

The UK left the European Union on January 31. Here we look at the latestfigures and key dates in the ongoing Brexit process.

Credit: PA - Press Association STUDIO    Duration: 00:50Published
Brexit briefing: 142 days until the end of the transition period [Video]

Brexit briefing: 142 days until the end of the transition period

The UK left the European Union on January 31. Here we look at the latestfigures and key dates in the ongoing Brexit process.

Credit: PA - Press Association STUDIO    Duration: 00:50Published
Belarus opposition tells Lukashenko to step down [Video]

Belarus opposition tells Lukashenko to step down

The opposition in Belarus rejected official election results handing President Alexander Lukashenko a landslide re-election victory on Monday, saying the poll was rigged and that talks needed to begin on a peaceful transfer of power. Emer McCarthy reports.

Credit: Reuters - Politics    Duration: 02:10Published

Fred Katayama journalist

Moderna shares jump on U.S. vaccine deal [Video]

Moderna shares jump on U.S. vaccine deal

Shares of Moderna jumped before paring their gains Wednesday after analysts said a $1.5 billion coronavirus vaccine supply agreement with the U.S. government could lead to similar deals with other countries. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:09Published
Don't sell Apple ahead of 5G: strategist [Video]

Don't sell Apple ahead of 5G: strategist

Apple shares have risen more than 50% this year, but O'Neil Global Advisors' Randy Watts says don't take profits ahead of their 5G rollout. He also tells Reuters' Fred Katayama that the U.S. dollar's recent drop makes emerging markets stocks and gold more attractive.

Credit: Reuters Studio    Duration: 04:16Published
CEOs form group to boost minority hiring in New York [Video]

CEOs form group to boost minority hiring in New York

Leaders from major U.S. companies, including banks and tech giants, have formed a group aimed at increasing the hiring of individuals from minority communities in New York. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:10Published
Dow, S&P rise; value outperforms [Video]

Dow, S&P rise; value outperforms

The Dow jumped 1%, the S&P 500 inched up and the Nasdaq closed lower Monday as investors extended a rotation into value stocks from heavyweight tech-related names while awaiting news on progress in a U.S. fiscal support bill. Fred Katayama reports.

Credit: Reuters Studio    Duration: 01:30Published

You Might Like


Tweets about this

EzzelarabLaila

laila ezzelarab RT @ColorMeRed: Gilead gets Hong Kong conditional approval for remdesivir to treat Covid-19 https://t.co/9n48lkpqwE via @PharmaTechFocus 1 week ago

ColorMeRed

Color Me Red 🩸🇺🇸 Gilead gets Hong Kong conditional approval for remdesivir for Covid-19 https://t.co/9n48lkpqwE via @PharmaTechFocus 1 week ago